News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
184,430 Results
Type
Article (13682)
Company Profile (26)
Press Release (170721)
Multimedia
Podcasts (23)
Webinars (6)
Section
Business (49943)
Career Advice (623)
Deals (9283)
Drug Delivery (38)
Drug Development (28607)
Employer Resources (70)
FDA (4848)
Job Trends (3953)
News (93303)
Policy (8082)
Tag
2027 Pharm Country Standard (1)
Academia (1089)
Academic (1)
Accelerated approval (8)
Adcomms (9)
Allergies (53)
Alliances (14174)
ALS (61)
Alzheimer's disease (510)
Antibody-drug conjugate (ADC) (63)
Approvals (4983)
Artificial intelligence (118)
Autoimmune disease (33)
Automation (8)
Bankruptcy (70)
Best Places to Work (3241)
BIOSECURE Act (6)
Biosimilars (89)
Biotechnology (12)
Bladder cancer (46)
Brain cancer (17)
Breast cancer (188)
Cancer (1265)
Cardiovascular disease (155)
Career advice (536)
Career pathing (14)
CAR-T (76)
CDC (21)
Celiac Disease (1)
Cell therapy (187)
Cervical cancer (11)
Clinical research (25400)
Collaboration (405)
Company closure (1)
Compensation (43)
Complete response letters (9)
COVID-19 (1132)
CRISPR (21)
C-suite (202)
Cystic fibrosis (30)
Data (2045)
Denatured (9)
Depression (39)
Diabetes (188)
Diagnostics (1797)
Digital health (10)
Diversity (8)
Diversity, equity & inclusion (29)
Drug discovery (57)
Drug pricing (77)
Drug shortages (17)
Duchenne muscular dystrophy (71)
Earnings (15289)
Editorial (26)
Employer branding (5)
Employer resources (65)
Events (22155)
Executive appointments (257)
FDA (5728)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (393)
Gene editing (40)
Generative AI (13)
Gene therapy (169)
GLP-1 (396)
Government (1287)
Grass and pollen (3)
Guidances (110)
Healthcare (5460)
HIV (30)
Huntington's disease (12)
IgA nephropathy (22)
Immunology and inflammation (70)
Immuno-oncology (15)
Indications (26)
Infectious disease (1220)
Inflammatory bowel disease (67)
Inflation Reduction Act (7)
Influenza (36)
Intellectual property (28)
Interviews (107)
IPO (3533)
IRA (30)
Job creations (813)
Job search strategy (459)
JPM (16)
Kidney cancer (4)
Labor market (23)
Layoffs (113)
Leadership (17)
Legal (1595)
Liver cancer (27)
Longevity (2)
Lung cancer (148)
Lymphoma (111)
Machine learning (8)
Management (23)
Manufacturing (178)
MASH (77)
Medical device (3247)
Medtech (3264)
Mergers & acquisitions (6036)
Metabolic disorders (454)
Multiple sclerosis (74)
NASH (19)
Neurodegenerative disease (79)
Neuropsychiatric disorders (17)
Neuroscience (898)
NextGen: Class of 2026 (2030)
Non-profit (1656)
Now hiring (5)
Obesity (192)
Opinion (67)
Ovarian cancer (44)
Pain (52)
Pancreatic cancer (46)
Parkinson's disease (96)
Partnered (13)
Patents (42)
Patient recruitment (112)
Peanut (19)
People (18172)
Pharmaceutical (10)
Pharmacy benefit managers (14)
Phase 1 (5635)
Phase 2 (10910)
Phase 3 (10342)
Pipeline (1344)
Policy (116)
Postmarket research (1210)
Preclinical (2045)
Press Release (29)
Prostate cancer (82)
Psychedelics (16)
Radiopharmaceuticals (65)
Rare diseases (238)
Real estate (1423)
Recruiting (23)
Regulatory (6502)
Reports (15)
Research institute (921)
Resumes & cover letters (83)
Rett syndrome (2)
RNA editing (2)
RSV (28)
Schizophrenia (47)
Series A (82)
Series B (56)
Service/supplier (2)
Sickle cell disease (25)
Special edition (4)
Spinal muscular atrophy (67)
Sponsored (10)
Startups (1215)
Stomach cancer (5)
Supply chain (23)
Tariffs (17)
The Weekly (14)
Vaccines (389)
Venture capital (24)
Weight loss (145)
Women's health (23)
Worklife (8)
Date
Last 7 days (145)
Last 30 days (445)
Last 365 days (7247)
2026 (598)
2025 (7487)
2024 (8618)
2023 (9760)
2022 (13255)
2021 (14811)
2020 (14300)
2019 (13759)
2018 (10626)
2017 (9759)
2016 (9356)
2015 (11019)
2014 (7555)
2013 (5950)
2012 (6396)
2011 (6745)
2010 (5808)
Location
Africa (273)
Alabama (10)
Alaska (4)
Arizona (63)
Arkansas (2)
Asia (13115)
Australia (2510)
California (2266)
Canada (591)
China (359)
Colorado (75)
Connecticut (96)
Delaware (97)
Europe (35938)
Florida (344)
Georgia (118)
Idaho (15)
Illinois (249)
India (21)
Indiana (154)
Iowa (3)
Japan (178)
Kansas (40)
Kentucky (14)
Louisiana (10)
Maine (12)
Maryland (338)
Massachusetts (1526)
Michigan (52)
Minnesota (142)
Missouri (39)
Montana (6)
Nebraska (7)
Nevada (32)
New Hampshire (11)
New Jersey (781)
New Mexico (7)
New York (760)
North Carolina (289)
Northern California (1085)
Ohio (73)
Oklahoma (4)
Oregon (5)
Pennsylvania (482)
Puerto Rico (4)
Rhode Island (4)
South America (384)
South Carolina (10)
Southern California (905)
Tennessee (32)
Texas (294)
United States (8540)
Utah (56)
Virginia (50)
Washington D.C. (10)
Washington State (219)
Wisconsin (21)
Wyoming (2)
184,430 Results for "boehringer mannheim group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Inflammatory bowel disease
Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere
The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.
January 27, 2026
·
2 min read
·
Tristan Manalac
Collaboration
Boehringer Ingelheim Bets up to Nearly $1B in ADC Play With AimedBio Deal
2025 has been a busy year for Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s AimedBio for an antibody-drug conjugate therapy for cancer.
October 15, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
January 28, 2026
·
7 min read
Press Releases
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
January 27, 2026
·
3 min read
Press Releases
Boehringer Ingelheim announces appointment to Board of Managing Directors
December 1, 2025
·
2 min read
Press Releases
Boehringer Ingelheim Secures Emergency Use Authorization for IVOMEC® (ivermectin) 1% Injection to Help Protect Cattle Against New World Screwworm
February 6, 2026
·
5 min read
Press Releases
Boehringer Ingelheim and CommonSpirit Health Collaborate to Improve Cardio-Kidney-Metabolic Screening and Diagnosis in Vulnerable Populations
January 13, 2026
·
5 min read
Press Releases
IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration
January 29, 2026
·
3 min read
Press Releases
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer
January 12, 2026
·
3 min read
Press Releases
Numab Therapeutics Achieves Milestone in Second Collaboration Project with Boehringer Ingelheim
December 19, 2025
·
2 min read
1 of 18,443
Next
